Affimed N.V. (AFMD)

$0.18 -0.10 (-34.95%)
Market Cap 2.92M
Revenue (ttm) 8.96M
Net Income (ttm) -114.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,279.69%
Debt to Equity Ratio 0.47
Volume 23,468,002
Avg Vol 19,511,936
Day's Range N/A - N/A
Shares Out 16.10M
Stochastic %K 15%
Beta 2.07
Analysts Sell
Price Target $6.83

Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, wh...

Industry: Biotechnology
Sector: Healthcare
Phone: 49 621 560030
Fax: 49 621 56003 649
Address:
Gottlieb-Daimler-Straße 2, Mannheim, Germany
deathknight
deathknight Nov. 14 at 12:25 AM
$AFMD not sure why but seems there are some big misunderstandings about how biopharma/biotech industry works. Below are some thoughts (just IMO): 1. Niche market is the go to choice for vast majority small biotechs, $AFMD is not exception here. Total available market (TAM) matters very little to small biotech and if they do aim to have commercialized products, serviceable obtainable market (SOM) is what really matters. Niche market normally means much less competition from big players and lower bars towards FDA approval. 2. There is no "trend" in the biotech world. Numerous small/big companies still uses approaches with decades of history for drug discovery -- especially for small molecule drugs. The only "trend" in pharma world is A) if the drug works and B) if it is safe. 3. Nobody in the world can force or guarantee a buyout. BUT, if a drug is promising (works and safe), scalable and doesn't need very complex logistics (unlike $ADAP's drug), it will draw serious interest.
1 · Reply
deathknight
deathknight Nov. 13 at 1:28 PM
$AFMD is it really so difficult to understand why there's no buyers immediately after the company published their stellar AFM13 + cord blood NK data with MD Anderson? The data is outstanding and certainly justifies a M&A or even a bid war IF it is from a monotherapy. Unfortunately it's combo therapy data meaning to make the drug perform, buyers need to acquire both pieces. Will anyone here buy a fancy car that comes without tires? It is just this simple. If certain buyer still wants the car, first thing they need to know is if the car is compatible with tires available to them (think Artiva) and ideally buy tires elsewhere to avoid being charged with high premium-- how much do you think companies like Artiva would ask if Roche tries to license their products AFTER they acquired $AFMD? Again, it's really not that difficult to understand.
1 · Reply
Hodl707
Hodl707 Nov. 11 at 3:38 PM
$AFMD we need to get hold of this guy worked for them got laid off
1 · Reply
Omarhabibeh
Omarhabibeh Nov. 11 at 2:49 PM
$AFMD Who bothers buying or selling 1,000 shares at $0.0001? If anyone knows this guy, please give him $10 and tell him to f**k off. 😅
1 · Reply
Think_Bigly
Think_Bigly Nov. 11 at 2:33 AM
$AFMD
0 · Reply
SRT2019
SRT2019 Nov. 10 at 11:03 PM
$AFMD Almost 11K shares traded today. Crazy!!
1 · Reply
Think_Bigly
Think_Bigly Nov. 9 at 10:40 PM
$AFMD Again: Roche should take this out at $400-$500M+ based on terms of their partner agreement. ~50% discount on NPV. https://www.genengnews.com/news/genentech-affimed-launch-up-to-5b-cancer-immunotherapy-collaboration/
0 · Reply
SRT2019
SRT2019 Nov. 9 at 7:01 PM
$AFMD per Grok, Artiva is still in play and hope it’s right. Signs are more towards either buyout or restructure. Fingers crossed 🤞
1 · Reply
Hodl707
Hodl707 Nov. 9 at 1:52 AM
$AFMD it’s all no hope all this just so we most likely get told that we lost fml!! I can’t take it any more I feel like I’m taking crazy pills
3 · Reply
Hodl707
Hodl707 Nov. 9 at 12:34 AM
$AFMD if you asume that the date is always the date for today well your wrong I looked up another case and as you can see the date is last update meaning someone filed something this is September
1 · Reply
Latest News on AFMD
No data available.
deathknight
deathknight Nov. 14 at 12:25 AM
$AFMD not sure why but seems there are some big misunderstandings about how biopharma/biotech industry works. Below are some thoughts (just IMO): 1. Niche market is the go to choice for vast majority small biotechs, $AFMD is not exception here. Total available market (TAM) matters very little to small biotech and if they do aim to have commercialized products, serviceable obtainable market (SOM) is what really matters. Niche market normally means much less competition from big players and lower bars towards FDA approval. 2. There is no "trend" in the biotech world. Numerous small/big companies still uses approaches with decades of history for drug discovery -- especially for small molecule drugs. The only "trend" in pharma world is A) if the drug works and B) if it is safe. 3. Nobody in the world can force or guarantee a buyout. BUT, if a drug is promising (works and safe), scalable and doesn't need very complex logistics (unlike $ADAP's drug), it will draw serious interest.
1 · Reply
deathknight
deathknight Nov. 13 at 1:28 PM
$AFMD is it really so difficult to understand why there's no buyers immediately after the company published their stellar AFM13 + cord blood NK data with MD Anderson? The data is outstanding and certainly justifies a M&A or even a bid war IF it is from a monotherapy. Unfortunately it's combo therapy data meaning to make the drug perform, buyers need to acquire both pieces. Will anyone here buy a fancy car that comes without tires? It is just this simple. If certain buyer still wants the car, first thing they need to know is if the car is compatible with tires available to them (think Artiva) and ideally buy tires elsewhere to avoid being charged with high premium-- how much do you think companies like Artiva would ask if Roche tries to license their products AFTER they acquired $AFMD? Again, it's really not that difficult to understand.
1 · Reply
Hodl707
Hodl707 Nov. 11 at 3:38 PM
$AFMD we need to get hold of this guy worked for them got laid off
1 · Reply
Omarhabibeh
Omarhabibeh Nov. 11 at 2:49 PM
$AFMD Who bothers buying or selling 1,000 shares at $0.0001? If anyone knows this guy, please give him $10 and tell him to f**k off. 😅
1 · Reply
Think_Bigly
Think_Bigly Nov. 11 at 2:33 AM
$AFMD
0 · Reply
SRT2019
SRT2019 Nov. 10 at 11:03 PM
$AFMD Almost 11K shares traded today. Crazy!!
1 · Reply
Think_Bigly
Think_Bigly Nov. 9 at 10:40 PM
$AFMD Again: Roche should take this out at $400-$500M+ based on terms of their partner agreement. ~50% discount on NPV. https://www.genengnews.com/news/genentech-affimed-launch-up-to-5b-cancer-immunotherapy-collaboration/
0 · Reply
SRT2019
SRT2019 Nov. 9 at 7:01 PM
$AFMD per Grok, Artiva is still in play and hope it’s right. Signs are more towards either buyout or restructure. Fingers crossed 🤞
1 · Reply
Hodl707
Hodl707 Nov. 9 at 1:52 AM
$AFMD it’s all no hope all this just so we most likely get told that we lost fml!! I can’t take it any more I feel like I’m taking crazy pills
3 · Reply
Hodl707
Hodl707 Nov. 9 at 12:34 AM
$AFMD if you asume that the date is always the date for today well your wrong I looked up another case and as you can see the date is last update meaning someone filed something this is September
1 · Reply
SRT2019
SRT2019 Nov. 8 at 9:03 PM
$AFMD $AFMD https://www.versteigerungskalender.de/insolvenzkalender/affimed-gmbh. Updated 11/8/25
1 · Reply
deathknight
deathknight Nov. 8 at 3:13 PM
$AFMD one reason I haven't considered is that we are facing significant administrative processing delay in the insolvency court system. Seems there has been a spike of insolvency filings in Germany. At minimum, we should have an public announcement regarding the outcome of the 9/29 creditor meeting. A formal creditor committee should be announced on this meeting and the info is required to be published.
2 · Reply
Hodl707
Hodl707 Nov. 8 at 3:03 AM
$AFMD Affimed isn’t just another biotech—it’s the clear leader in NK-cell engagers. Others are circling the same space, but they don’t have the clinical proof + pharma partnership + proprietary platform trifecta.
0 · Reply
Hodl707
Hodl707 Nov. 8 at 2:00 AM
$AFMD does anybody know how to double check this Yes, the German insolvency docket for Affimed does show a new publication stamp dated November 8, 2025—but the contents of that filing have not yet been made public. This aligns with backend timing: the filing was likely submitted today (Nov 7) and will hit public record tomorrow.
1 · Reply
deathknight
deathknight Nov. 7 at 9:19 PM
$AFMD Can anyone actually sell at 0.0000001? My broker doesn't even allow orders below 0.0001. How did this 1000 shares get traded?
2 · Reply
deathknight
deathknight Nov. 7 at 5:31 PM
$AFMD Not a single share changed hand since yesterday morning.
1 · Reply
DrPump_
DrPump_ Nov. 6 at 10:14 PM
$AFMD registered my Mail: mailto:[email protected] with this message: “Who is the lady in the pic?” But didn’t get a reply … 😩😩😩
2 · Reply
Hodl707
Hodl707 Nov. 6 at 6:29 PM
$AFMD if someone snaps up the whole enchilada (Affimed N.V. shell + GmbH ops + all the IP intact via a clean asset sale or restructuring approved by the Mannheim court and admin Tobias Wahl), they absolutely inherit the full Genentech collaboration rights.   That means every damn milestone payment (up to $5B total: dev stuff like $250M, regulatory $1.1B, commercial/sales thresholds $3.6B) and tiered royalties on sales flow straight to the new owner.
1 · Reply
deathknight
deathknight Nov. 6 at 3:47 PM
$AFMD wow didn't realize we can go lower than 0.0001. We are serious trading lower than the majority of worthless meme coins.
0 · Reply
deathknight
deathknight Nov. 6 at 1:10 PM
$AFMD I dont think anyone here would appreciate such a bad joke. This Affimedusa.com website was registered at 1am EST today.
2 · Reply
bioman_the_dude
bioman_the_dude Nov. 6 at 6:16 AM
$AFMD what dis https://affimedusa.com/
3 · Reply
SRT2019
SRT2019 Nov. 6 at 1:03 AM
$AFMD https://www.versteigerungskalender.de/insolvenzkalender/affimed-gmbh. Seems like there is a recent update but I can’t access it. Publication 11/6/25
1 · Reply